epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
Conditions
Interventions
Herombopag treatment group:NA
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by histopathology; 2. Age: 18-75 years old; 3. ECOG score: 0-2; 4. Being treated with PARP inhibitors: PARP inhibitor combined with chemotherapy regimen, PARP inhibitor combined with bevacizumab; 5. Occurrence PLT<100×10^9/L; 6. Normal function of major organs; 7. The researchers determined that patients could be treated with hexapopal.
Exclusion criteria
Exclusion criteria: 1. The patient is undergoing an intervention study; 2. Failure to understand the nature of the research or to obtain informed consent; 3. Other situations deemed unsuitable for inclusion in the study by the researcher;
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with PARP reduction or suspension;Changes in PAPR Adjustment Volume; | — |
Primary
| Measure | Time frame |
|---|---|
| Proportion of responding patients; | — |
Countries
China
Contacts
Public ContactLi Qiling
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed